Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme (Q33358912)

26 July 2017

title

Phase 2 study of temozolomide and Caelyx in patients with recurrent glioblastoma multiforme (English)

1 reference

26 July 2017

0 references

1 reference

Susan L Chua

1

1 reference

26 July 2017

Mark A Rosenthal

2

1 reference

26 July 2017

Shirley S Wong

3

1 reference

26 July 2017

David M Ashley

4

1 reference

26 July 2017

Anne-Marie Woods

5

1 reference

26 July 2017

Anthony Dowling

6

1 reference

26 July 2017

Lawrence M Cher

7

1 reference

26 July 2017

language of work or name

1 reference

1 January 2004

1 reference

26 July 2017

1 reference

26 July 2017

volume

6

1 reference

26 July 2017

issue

1

1 reference

26 July 2017

page(s)

38-43

1 reference

Current and future developments in the use of temozolomide for the treatment of brain tumours

26 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

21 June 2018

Cancer statistics, 2002

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

A phase II study of extended low-dose temozolomide in recurrent malignant gliomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

Descriptive epidemiology of primary brain and CNS tumors: results from the Central Brain Tumor Registry of the United States, 1990-1994

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

Chemotherapy for brain tumors of astrocytic and oligodendroglial lineage: the past decade and where we are heading

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

Multicenter phase II trial of temozolomide in patients with glioblastoma multiforme at first relapse

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

PCV chemotherapy for recurrent glioblastoma multiforme.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

High intratumoural accumulation of stealth liposomal doxorubicin (Caelyx) in glioblastomas and in metastatic brain tumours

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

Temozolomide and treatment of malignant glioma.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

Multicenter phase II trial of temozolomide in patients with anaplastic astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

New chemotherapy options for the treatment of malignant gliomas

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

Liposome-mediated therapy of intracranial brain tumors in a rat model

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

Optimal two-stage designs for phase II clinical trials

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

Long-term stabilization in patients with malignant glioma after treatment with liposomal doxorubicin

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

An Australian experience with temozolomide for the treatment of recurrent high grade gliomas

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

Neuro-oncology clinical trials: promise and pitfalls

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

Schedule-dependent activity of temozolomide plus CPT-11 against a human central nervous system tumor-derived xenograft.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

Phase II study of combination taxol and estramustine phosphate in the treatment of recurrent glioblastoma multiforme.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

KRN8602 (MX2-hydrochloride): an active new agent for the treatment of recurrent high-grade glioma.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

Sequential administration of temozolomide and fotemustine: depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

Response criteria for phase II studies of supratentorial malignant glioma

31 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=1871967

Doxorubicin encapsulated in sterically stabilized liposomes for the treatment of a brain tumor model: biodistribution and therapeutic efficacy

31 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/14769139

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1215/S1152851703000188

1 reference

26 July 2017

1 reference

26 July 2017

1 reference